Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
ApexOnco Front Page
Recent articles
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
